Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MoonLake ImmunotherapeuticsMLTX 28 Debt-to-Equity is 0.40 as of Mar. 2026, which is 3900% above its 10-year median of 0.01. GuruFocus rates MLTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 966 Biotechnology companies, MoonLake Immunotherapeutics ranks worse than 69.77% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for MoonLake Immunotherapeutics's Debt-to-Equity or its related term are showing as below:
MLTX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.29 Med: 0.01 Max: 0.4
Current: 0.4
During the past 5 years, the highest Debt-to-Equity Ratio of MoonLake Immunotherapeutics was 0.40. The lowest was -1.29. And the median was 0.01.
MLTX's Debt-to-Equity is ranked worse than 69.77% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs MLTX: 0.40
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
MoonLake Immunotherapeutics Debt-to-Equity Related Terms
MoonLake Immunotherapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLTX vs FTRE, SEPN, URGN: Debt-to-Equity Comparison
For the Biotechnology subindustry, MoonLake Immunotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MoonLake Immunotherapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where MoonLake Immunotherapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MoonLake Immunotherapeutics (MLTX) has a Debt-to-Equity of 0.40 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MoonLake Immunotherapeutics and its competitors. This is 3900% above median its historical median of 0.01. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #674 out of 966 companies in the Biotechnology industry, placing it in the top 69.8%.
Is MoonLake Immunotherapeutics' Debt-to-Equity too high?
MoonLake Immunotherapeutics' current Debt-to-Equity of 0.40 is 3900% above median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. MoonLake Immunotherapeutics' value of 0.40 is 150% above this industry median. Based on the distribution chart, MoonLake Immunotherapeutics ranks #674 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MoonLake Immunotherapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Debt-to-Equity compare to FTRE and SEPN?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #674 out of 966 companies for Debt-to-Equity. This places MoonLake Immunotherapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. MoonLake Immunotherapeutics' value of 0.40 is 150% above this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.16, MoonLake Immunotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MoonLake Immunotherapeutics's current Debt-to-Equity of 0.40 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MoonLake Immunotherapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MoonLake Immunotherapeutics's current Debt-to-Equity is 0.40, which is 3900% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MLTX) has a current Debt-to-Equity of 0.40. The current Debt-to-Equity is 0.40, which is 3900% above median its 10-year median of 0.01 and 150% above the Biotechnology industry median of 0.16. MoonLake Immunotherapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MLTX), the current Debt-to-Equity is 0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
28GF Score
Get the complete analysis for MLTX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLTX has been successfully added to your 
